Market research
CMPI Checkmate Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 231M
- P/E ratio
- Not available
- Analyst target
- 12.5
- Dividend yield
- 0.0%
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1628181083
- Market cap
- 231M
- P/E ratio
- Not available
- Analyst target
- 12.5
- Dividend yield
- 0.0%
- Beta
- Not available
About
About Checkmate Pharmaceuticals Inc
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CMPI discussion.
5 years, 4 months ago
Checkmate Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 50.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Checkmate Pharmaceuticals, Inc gets an overall score of 1/5.